RIGEL PHARMACEUTICAL with less fundamental stars is reduced to Neutral
RIGEL PHARMACEUTICAL (US), a company active in the Pharmaceuticals industry, loses a star(s) at the fundamental level and sees its general evaluation downgraded. The independent financial analyst theScreener just removed a fundamental star(s) for a 2 over 4-star rating. As such, market behaviour remains unchanged and is evaluated as moderately risky. theScreener believes that the loss of a star(s) merits downgrade to the general evaluation of the title, which passes to Neutral. As of the analysis date April 5, 2022, the closing price was USD 3.09 and its expected value was estimated at USD 2.93.Rigel Pharmaceuticals is a biotechnology company focused on discovering, developing and providing small molecule drugs that improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's research focuses on signaling pathways that are critical to disease mechanisms. The company's approved product is TAVALISSE? (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. In addition, the company has product candidates in development with partners BerGenBio ASA, Daiichi Sankyo, Aclaris Therapeutics, and AstraZeneca AB.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.